Pal et al. in a study of the effect of fisetin alone and in combination therapy with sorafenib, demonstrated that fisetin enhanced sorafenib-induced apoptosis and abrogated tumor growth in athymic nude mice xenografted with BRAF-mutated melanoma cells through the inhibition of the expressions of activated components of PI3K and MAPK pathways [141]. The gene discussed is BRAF; the disease is neoplasm.